KRAS Signaling Pathway Alterations in Microsatellite Unstable Gastrointestinal Cancers

Advances in Cancer Research

Volumn 109, Issue C, 2010, Pages 123-

  Velho, Sérgia ^a   Corso, Giovanni ^a,b,c   Oliveíra, Carla ^a,d   Seruca, Raquel ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF SIENA   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICROSATELLITE DNA;

BOOK; CARCINOGENESIS; CLINICAL FEATURE; COLORECTAL CANCER; CPG ISLAND; DIGESTIVE SYSTEM CANCER; EPIGENETICS; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 78149389848     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380890-5.00004-1     Document Type: Chapter

References (117)

1. Ahuja N., Mohan A.L., Li Q., Stolker J.M., Herman J.G., Hamilton S.R., Baylin S.B., Issa J.-P.J. Association between CpG Island methylation and microsatellite instability in colorectal cancer. Cancer Res. 1997, 57:3370-3374.
2. An C., Choi I.S., Yao J.C., Worah S., Xie K., Mansfield P.F., Ajani J.A., Rashid A., Hamilton S.R., Wu T.T. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res. 2005, 11:656-663.
3. Arnold C.N., Goel A., Boland C.R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 2003, 106:66-73.
4. Banerjea A., Hands R.E., Powar M.P., Bustin S.A., Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis. 2009, 11:601-608.
5. Barber T.D., Vogelstein B., Kinzler K.W., Velculescu V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 2004, 351:2883.
6. Becker J.C., Muller-Tidow C., Stolte M., Fujimori T., Tidow N., Ilea A.M., Brandts C., Tickenbrock L., Serve H., Berdel W.E., Domschke W., Pohle T. Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int. J. Oncol. 2006, 29:615-623.
7. Beghelli S., de Manzoni G., Barbi S., Tomezzoli A., Roviello F., Di Gregorio C., Vindigni C., Bortesi L., Parisi A., Saragoni L., Scarpa A., Moore P. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006, 139:347-356.
8. Brennetot C., Duval A., Hamelin R., Pinto M., Oliveira C., Seruca R., Schwartz S.J. Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology 2003, 125:1282.
9. Cai G., Xu Y., Lu H., Shi Y., Lian P., Peng J., Du X., Zhou X., Guan Z., Shi D., Cai S. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int. J. Colorectal Dis. 2008, 23:365-373.
10. Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64:7678-7681.
11. Carethers J., Chauhan D., Fink D., Nebel S., Bresalier R., Howell S., Boland C. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
12. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., Cabrera B.L., Goel A., Arnold C.A., Miyai K., Boland C.R. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004, 126:394-401.
13. Carvalho B., Pinto M., Cirnes L., Oliveira C., Machado J.C., Suriano G., Hamelin R., Carneiro F., Seruca R. Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. Eur. J. Cancer 2003, 39:1222-1227.
14. Castells A., Castellví-Bel S., Balaguer F. Concepts in familial colorectal cancer: Where do we stand and what is the future?. Gastroenterology 2009, 137:404-409.
15. Chadee D., Kyriakis J. A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation. Cell Cycle 2004, 3:1227-1229.
16. Chang E., Dorsey P., Frankhouse J., Lee R., Walts D., Johnson W., Anadiotis G., Johnson N. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch. Surg. 2009, 144:511-515.
17. Clark A.J., Barnetson R., Farrington S.M., Dunlop M.G. Prognosis in DNA mismatch repair deficient colorectal cancer: Are all MSI tumours equivalent?. Fam. Cancer 2004, 3:85-91.
18. Corso G., Pedrazzani C., Marrelli D., Pascale V., Pinto E., Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch. Surg. 2009, 144:722-727.
19. Davalos V., Dopeso H., Velho S., Ferreira A.M., Cirnes L., Diaz-Chico N., Bilbao C., Ramirez R., Rodriguez G., Falcon O., Leon L., Niessen R.C., et al. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 2006, 26:308-311.
20. Deng G., Bell I., Crawley S., Gum J., Terdiman J.P., Allen B.A., Truta B., Sleisenger M.H., Kim Y.S. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 2004, 10:191-195.
21. Des Guetz G., Schischmanoff O., Nicolas P., Perret G.-Y., Morere J.-F., Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 2009, 45:1890-1896.
22. Des Guetz G., Uzzan B., Nicolas P., Schischmanoff O., Morere J.-F. Microsatellite instability: A predictive marker in metastatic colorectal cancer?. Targ. Oncol. 2009, 4:57-62.
23. Des Guetz G.T., Uzzan B., Nicolas P., Schischmanoff O., Perret G.-Y., Morere J.-F.O. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res. 2009, 29:1615-1620.
24. Domingo E., Espin E., Armengol M., Oliveira C., Pinto M., Duval A., Brennetot C., Seruca R., Hamelin R., Yamamoto H., Schwartz S. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004, 39:138-142.
25. Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., Westra J., Frebourg T., Espín E., Armengol M., Hamelin R., Yamamoto H., et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet. 2004, 41:664-668.
26. Domingo E., Niessen R.C., Oliveira C., Alhopuro P., Moutinho C., Espin E., Armengol M., Sijmons R.H., Kleibeuker J.H., Seruca R., Aaltonen L.A., Imai K., et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005, 24:3995-3998.
27. Dong S.M., Lee E.J., Jeon E.S., Park C.K., Kim K.-M. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod. Pathol. 2004, 18:170-178.
28. dos Santos N., Seruca R., Constância M., Seixas M., Sobrinho-Simões M. Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis. Gastroenterology 1996, 110:38-44.
29. Drescher K., Sharma P., Watson P., Gatalica Z., Thibodeau S., Lynch H. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam. Cancer 2009, 8:231-239.
30. Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: Toward a new concept of target genes for instability. Cancer Res. 2002, 62:2447-2454.
31. Ekstrand A., Jönsson M., Lindblom A., Borg Å., Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam. Cancer 2009, 9:125-129.
32. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
33. Fleisher A.S., Esteller M., Tamura G., Rashid A., Stine O.C., Yin J., Zou T.T., Abraham J.M., Kong D., Nishizuka S., James S.P., Wilson K.T., et al. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001, 20:329-335.
34. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 2002, 3:663-672.
35. Gazzoli I., Loda M., Garber J., Syngal S., Kolodner R.D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002, 62:3925-3928.
36. Goel A., Nguyen T.-P., Leung H.-C.E., Nagasaka T., Rhees J., Hotchkiss E., Arnold M., Banerji P., Koi M., Kwok C.-T., Packham D., Lipton L., et al. De novo constitutional MLH epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int. J. Cancer 2010, 9999.
37. Greenson J.K., Huang S.-C., Herron C., Moreno V., Bonner J.D., Tomsho L.P., Ben-Izhak O., Cohen H.I., Trougouboff P., Bejhar J., Sova Y., Pinchev M., et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am. J. Surg. Pathol. 2009, 33:126-133. doi:10.1097/PAS.0b013e31817ec2b1.
38. Gryfe R., Kim H., Hsieh E.T., Aronson M.D., Holowaty E.J., Bull S.B., Redston M., Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000, 342:69-77.
39. Gu M., Kim D., Bae Y., Choi J., Kim S., Song S. Analysis of microsatellite instability, protein expression and methylation status of hMLH1 and hMSH2 genes in gastric carcinomas. Hepatogastroenterology 2009, 56:899-904.
40. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
41. Hitchins M., Williams R., Cheong K., Halani N., Lin V.A., Packham D., Ku S., Buckle A., Hawkins N., Burn J., Gallinger S., Goldblatt J., et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 2005, 129:1392-1399.
42. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29:673-680.
43. Ionov Y., Peinado M.A., Malkhosyan S., Shibata D., Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561.
44. Jakowlew S. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006, 25:435-457.
45. Jass J. HNPCC and sporadic MSI-H colorectal cancer: A review of the morphological similarities and differences. Fam. Cancer 2004, 3:93-100.
46. Jass J.R. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat. Clin. Pract. Oncol. 2005, 2:398-405.
47. Jass J.R. Colorectal cancer: A multipathway disease. Crit. Rev. Oncog. 2006, 12:273-287.
48. Jass J.R. Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg. Oncol. 2007, 16:7-9.
49. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006, 7:335-346.
50. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003, 284:31-53.
51. Kambara T., Simms L., Whitehall V., Spring K., Wynter C., Walsh M., Barker M., Arnold S., McGivern A., Matsubara N., Tanaka N., Higuchi T., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144.
52. Kim Y.H., Kakar S., Cun L., Deng G., Kim Y.S. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int. J. Cancer 2008, 123:2587-2593.
53. Kim Y.-H., Min B.-H., Kim S., Choi H., Kim K.-M., Chun H.-K., Lee H., Kim J., Chang D., Son H., Rhee P.-L., Rhee J., et al. Difference between proximal and distal microsatellite-unstable sporadic colorectal cancers: Analysis of clinicopathological and molecular features and prognoses. Ann. Surg. Oncol. 2010.
54. Kuismanen S.A., Holmberg M.T., Salovaara R., de la Chapelle A., Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am. J. Pathol. 2000, 156:1773-1779.
55. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
56. Leite M., Corso G., Sousa S., Milanezi F., Afonso L.P., Henrique R., Soares J.M., Castedo S., Carneiro F., Roviello F., Oliveira C., Seruca R. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int. J. Cancer 2010, (Epub ahead of print).
57. Li V., Wong C., Chan T., Chan A., Zhao W., Chu K.-M., So S., Chen X., Yuen S., Leung S. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005, 5:29.
58. Lièvre A., Bachet J., Corre D.L., Boige V., Landi B., Emile J., Côté J., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
59. Lièvre A., Bachet J., Boige V., Cayre A., Corre D.L., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
60. Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., Tsui W.Y., Kong C.K., et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 2009, 41:112-117.
61. Lubomierski N., Plotz G., Wormek M., Engels K., Kriener S., Trojan J., Jungling B., Zeuzem S., Raedle J. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 2005, 104:952-961.
62. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N. Engl. J. Med. 2003, 348:919-932.
63. Lynch H.T., Lanspa S., Smyrk T., Boman B., Watson P., Lynch J. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet. Cytogenet. 1991, 53:143-160.
64. Machado A.M., Figueiredo C., Touati E., Máximo V., Sousa S., Michel V., Carneiro F., Nielson F.C., Seruca R., Rasmussen L.J. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin. Cancer Res. 2009, 15:2995-3002.
65. Machado A.M., Figueiredo C., Seruca R., Rasmussen L.J. Helicobacter pylori infection generates genetic instability in gastric cells. Biochim. Biophys. Acta 2010.
66. Malesci A., Laghi L., Bianchi P., Delconte G., Randolph A., Torri V., Carnaghi C., Doci R., Rosati R., Montorsi M., Roncalli M., Gennari L., et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin. Cancer Res. 2007, 13:3831-3839.
67. Mammano E., Belluco C., Sciro M., Mencarelli R., Agostini M., Michelotto M., Marchet A., Nitti D. Epidermal growth factor receptor (EGFR): Mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006, 26:3547-3550.
68. Miyaki M., Iijima T., Yamaguchi T., Takahashi K., Matsumoto H., Yasutome M., Funata N., Mori T. Mutations of the PIK3CA gene in hereditary colorectal cancers. Int. J. Cancer 2007, 121:1627-1630.
69. Miyakura Y., Sugano K., Akasu T., Yoshida T., Maekawa M., Saitoh S., Sasaki H., Nomizu T., Konishi F., Fujita S., Moriya Y., Nagai H. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin. Gastroenterol. Hepatol. 2004, 2:147-156.
70. Moutinho C., Mateus A., Milanezi F., Carneiro F., Seruca R., Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008, 8:10.
71. Niessen R.C., Hofstra R.M., Westers H., Ligtenberg M.J., Kooi K., Jager P.O., de Groote M.L., Dijkhuizen T., Olderode-Berends M.J., Hollema H., Kleibeuker J.H., Sijmons R.H. Germline hypermethylation of the MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009, 48:737-744.
72. Nosho K., Irahara N., Shima K., Kure S., Kirkner G.J., Schernhammer E.S., Hazra A., Hunter D.J., Quackenbush J., Spiegelman D., Giovannucci E.L., Fuchs C.S., et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008, 3:e3698.
73. O'Brien M.J. Hyperplastic and serrated polyps of the colorectum. Gastroenterol. Clin. North Am. 2007, 36:947-968.
74. O'Brien M.J., Yang S., Mack C., Xu H., Huang C.S., Mulcahy E., Amorosino M., Farraye F.A. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006, 30:1491-1501.
75. Ogino S., Meyerhardt J.A., Cantor M., Brahmandam M., Clark J.W., Namgyal C., Kawasaki T., Kinsella K., Michelini A.L., Enzinger P.C., Kulke M.H., Ryan D.P., et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin. Cancer Res. 2005, 11:6650-6656.
76. Ogino S., Cantor M., Kawasaki T., Brahmandam M., Kirkner G., Weisenberger D., Campan M., Laird P., Loda M., Fuchs C. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006, 55:1000-1006.
77. Ogino S., Nosho K., Kirkner G.J., Kawasaki T., Meyerhardt J.A., Loda M., Giovannucci E.L., Fuchs C.S. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
78. Oliveira C., Seruca R., Seixas M., Sobrinho-Simões M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": A study of the TGFbeta RII; IGFII R, and BAX genes. Am. J. Pathol. 1998, 153:1211-1219.
79. Oliveira C., Pinto M., Duval A., Brennetot C., Domingo E., Espin E., Armengol M., Yamamoto H., Hamelin R., Seruca R., Schwartz S. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003, 22:9192-9196.
80. Oliveira C., Westra J., Arango D., Ollikainen M., Domingo E., Ferreira A. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum. Mol. Genet. 2004, 13:2303-2311.
81. Oliveira C., Velho S., Domingo E., Preto A., Hofstra R.M.W., Hamelin R., Yamamoto H., Seruca R., Schwartz S. Concomitant RASSF1A hypermethylation and KRAS//BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 2005, 24:7630-7634.
82. Ottini L., Falchetti M., Lupi R., Rizzolo P., Agnese V., Colucci G., Bazan V., Russo A. Patterns of genomic instability in gastric cancer: Clinical implications and perspectives. Ann. Oncol. 2006, 17:97-102.
83. Pedrazzani C., Corso G., Velho S., Leite M., Pascale V., Bettarini F., Marrelli D., Seruca R., Roviello F. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Fam. Cancer 2009, 8:215-220.
84. Peltomaki P. DNA mismatch repair and cancer. Mutat. Res. 2001, 488:77-85.
85. Peltomäki P., Vasen H. Mutations associated with HNPCC predisposition: Update of ICG-HNPCC/INSiGHT mutation database. Dis. Markers 2004, 20:269-276.
86. Pinto M., Oliveira C., Machado J.C., Cirnes L., Tavares J., Carneiro F., Hamelin R., Hofstra R., Seruca R., Sobrinho-Simões M. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathologic profile. Lab. Invest. 2000, 80:1915-1923.
87. Pinto M., Wu Y., Mensink R.G.J., Cirnes L., Seruca R., Hofstra R.M.W. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. Cancer Genet. Cytogenet. 2008, 180:110-114.
88. Preto A., Figueiredo J., Velho S., Ribeiro A.S., Soares P., Oliveira C., Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations. J. Pathol. 2008, 214:320-327.
89. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
90. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349:247-257.
91. Rustgi A. The genetics of hereditary colon cancer. Genes Dev. 2007, 21:2525-2538.
92. Samowitz W.S., Slattery M.L., Sweeney C., Herrick J., Wolff R.K., Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res. 2007, 5:165-170.
93. Samuels Y., Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004, 3:1221-1224.
94. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
95. Seruca R., Santos N., David L., Constância M., Barroca H., Carneiro F., Seixas M., Peltomaki P., Lothe R., Sobrinho-Simões M. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int. J. Cancer 1995, 64:32-36.
96. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R., Issa J.-P.J. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 2007, 104:18654-18659.
97. Shia J., Klimstra D.S., Li A.R., Qin J., Saltz L., Teruya-Feldstein J., Akram M., Chung K.Y., Yao D., Paty P.B., Gerald W., Chen B. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol. 2005, 18:1350-1356.
98. Sinicrope F.A., Sargent D.J. Clinical implications of microsatellite instability in sporadic colon cancers. Curr. Opin. Oncol. 2009, 21:369-373.
99. Smith G., Carey F.A., Beattie J., Wilkie M.J.V., Lightfoot T.J., Coxhead J., Garner R.C., Steele R.J.C., Wolf C.R. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. USA 2002, 99:9433-9438.
100. Suter C.M., Martin D.I., Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 2004, 36:497-501.
101. Takehana T., Kunitomo K., Suzuki S., Kono K., Fujii H., Matsumoto Y., Ooi A. Expression of epidermal growth factor receptor in gastric carcinomas. Clin. Gastroenterol. Hepatol. 2003, 1:438-445.
102. Tanaka J., Watanabe T., Kanazawa T., Tada T., Kazama Y., Tanaka T., Nagawa H. Left-sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones. J. Surg. Oncol. 2007, 96:611-618.
103. Thomas J., Boland C.R. Structure and function of the components of the human DNA mismatch repair system. Int. J. Cancer 2006, 119:2030-2035.
104. Toyota M., Ahuja N., Ohe-Toyota M., Herman J., Baylin S., Issa J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96:8681-8686.
105. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., Costinean S., Sandhu S.K., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA 2010, 107:6982-6987.
106. van Engeland M., Roemen G., Brink M., Pachen M., Weijenberg M., de Bruïne A., Arends J., van den Brandt P., de Goeij A., Herman J. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002, 21:3792-3795.
107. Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., Schwartz J.S., Duval A., Carneiro F., Machado J.C. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 2005, 41:1649-1654.
108. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Oliveira C., Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
109. Velho S., Oliveira C., Paredes J., Sousa S., Leite M., Matos P., Milanezi F., Ribeiro A.S., Mendes N., Licastro D., Karhu A., Oliveira M.J., et al. Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum. Mol. Genet. 2010, 19:697-706.
110. Weisenberger D., Siegmund K., Campan M., Young J., Long T., Faasse M., Kang G., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
111. Wheeler J.M.D., Loukola A., Aaltonen L.A., Mortensen N.J.M., Bodmer W.F. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+sporadic colorectal cancers. J. Med. Genet. 2000, 37:588-592.
112. Whitehall V., Wynter C., Walsh M., Simms L., Purdie D., Pandeya N., Young J., Meltzer S., Leggett B., Jass J. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002, 62:6011-6014.
113. Wynter C., Walsh M., Higuchi T., Leggett B., Young J., Jass J. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 2004, 53:573-580.
114. Yamamoto H., Min Y., Itoh F., Imsumran A., Horiuchi S., Yoshida M., Iku S., Fukushima H., Imai K. Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability. Genes Chromosomes Cancer 2002, 33:322-325.
115. Yang S., Farraye F.A., Mack C., Posnik O., O'Brien M.J. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: Relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004, 28:1452-1459.
116. Yuan Z., Shin J., Wilson A., Goel S., Ling Y.-H., Ahmed N., Dopeso H., Jhawer M., Nasser S., Montagna C., Fordyce K., Augenlicht L.H., et al. An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res. 2009, 69:7811-7818.
117. Zlobec I., Bihl M., Schwarb H., Terracciano L., Lugli A. Clinicopathological and protein characterization of BRAF and KRAS mutated colorectal cancer and implications for prognosis. Int. J. Cancer 2009.